Objective:

To present the first generation of FDA-approved technologies for myopia management in the United States, highlighting their role in shaping treatment standards.

Approach:

• CooperVision MiSight 1 day: A daily disposable soft contact lens designed to correct myopia and slow its progression in children aged 8 to 12, featuring ActivControl Technology that incorporates concentric rings of alternating vision correction and treatment zones.
• Essilor Stellest: A spectacle lens for children aged 6 to 12 that combines vision correction with myopia management using Highly Aspherical Lenslet Target (H.A.L.T.) technology, which creates a 3-dimensional volume of myopic defocus.
• Johnson & Johnson Vision Acuvue Abiliti: Orthokeratology contact lenses worn overnight to correct refractive error and manage myopia progression in children, approved for reducing refractive error up to 6.00 D and designed to reshape the cornea during sleep.

Key Findings:

• MiSight 1 day demonstrated a 59% reduction in myopia progression and 52% in axial elongation over 3 years compared to single-vision lenses.
• Essilor Stellest lenses slowed myopia progression and eye elongation in children aged 6 to 12, with clinically validated results.
• Acuvue Abiliti Overnight lenses reduced axial elongation by an average of 0.28 mm over 2 years compared to single-vision spectacle lenses.

Interpretation:

The FDA has approved several innovative technologies for myopia management, which are beginning to shape treatment standards in the U.S.

Limitations:

• The article does not discuss the availability of certain products like Hoya’s MiyoSmart and Zeiss MyoCare in the U.S.
• The pace of myopia management technology development in the U.S. is slower compared to other global markets.

Conclusion:

The introduction of these FDA-approved technologies marks a significant advancement in the management of pediatric myopia.